Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
Retrieved on:
Wednesday, September 22, 2021
Philanthropy, Health, Other Philanthropy, General Health, Pharmaceutical, Biotechnology, Knowledge, Health, Mortality, United Nations Humanitarian Response Depot, Hematology, Child, Vaccine, Iwin, Safety, Investment, Health education, Failure, Mark (given name), Public sector, Takeda Pharmaceutical Company, U.S. Securities and Exchange Commission, Refugee, Measles, Disease, CEO, Leadership, Genetics, Pathfinder International, Global, Partnership, SDG, World Food Programme, Woman, Annual report, TSE, WFP, TAK, Acquisition, CSR, Face, R, Pregnancy, Time, Projection, Adoption, Humble Bundle, IntraHealth International, Climate change, Limit cycle, Emergency, Patient, Public–private partnership, Nursing, Logistics, COVID-19, Quality of life, Pharmaceutical industry, Medicine, Birth control, Renewable energy, Risk management
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced the addition of four partnerships to its Global Corporate Social Responsibility (CSR) Program , which makes long-term commitments to strengthen health systems and improve access to healthcare for all in developing and emerging countries.
Key Points:
- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced the addition of four partnerships to its Global Corporate Social Responsibility (CSR) Program , which makes long-term commitments to strengthen health systems and improve access to healthcare for all in developing and emerging countries.
- The project will strengthen access to equitable health services, build community resilience to climate shocks and help women forge their own path to a healthier future.
- Each project addresses strengthening health systems in unique ways and aligns with countries national health needs.
- In this release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.